Mayo Clinic Rochester, Minnesota
Medical Oncologist
Conquer Cancer, the ASCO Foundation
Optimizing therapies for patients with early-stage triple-negative breast cancer
Patients with triple-negative breast cancer (TNBC) face higher risks of early recurrence and death compared to other breast cancer subtypes. Chemotherapy, often combined with immunotherapy, is the standard treatment, even for early-stage TNBC. Most patients receive a combination of two to five drugs, increasing the risk of side effects. Prior research has shown that patients with early-stage TNBC who did not receive chemotherapy and had high levels of tumor-infiltrating lymphocytes (TILs), a cancer fighting immune cell, had a lower risk of developing metastatic disease and dying.
For Dr. Leon-Ferre’s Conquer Cancer Award supported by BCRF, he and his team will evaluate if TILs and tumor proliferation biomarkers can refine prediction for risk of recurrence in TNBC patients who did not receive chemotherapy. The team hopes to incorporate these markers into future clinical trials so that the chemotherapy regimen can be personalized, potentially reducing the number of drugs needed and minimizing side effects while maintaining effective cancer control.
Roberto Leon-Ferre, MD is a medical oncologist and researcher focused on breast cancer, with a special interest in triple-negative breast cancer. His research evaluates factors that impact the prognosis of patients with breast cancer and their response to anti-cancer treatments. His goal is to increase our understanding of how the immune system can be leveraged to optimize treatment strategies for patients with breast cancer. He is interested in tailoring treatment approaches in a personalized manner. His goal is for every patient to receive the right intensity of treatment so that cancer is controlled or eradicated without more side effects than necessary.
2024
Please remember BCRF in your will planning. Learn More
3X MATCH
Today, your gift is TRIPLED for 3X the impact on lifesaving research.
